There were 1,938 press releases posted in the last 24 hours and 440,628 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image